What is DalCor Pharmaceuticals?
DalCor Pharmaceuticals is a biopharmaceutical firm focused on precision medicine for cardiovascular diseases. Their lead candidate, dalcetrapib, is a pharmacogenetic treatment designed to lower the risk of recurrent myocardial infarction in patients with a specific genetic profile (AA genotype at the rs1967309 location in the ADCY9 gene). The company is currently advancing dalcetrapib through the Dal-GenE-2 Phase 3 clinical trial, building on positive outcomes from the dal-GenE trial. DalCor's strategic focus targets patients with cardiovascular conditions, including those with obesity, diabetes, and hypertension, positioning them in a critical segment of the healthcare market.
How much funding has DalCor Pharmaceuticals raised?
DalCor Pharmaceuticals has raised a total of $230M across 3 funding rounds:
Series A
$50M
Series B
$100M
Series D
$80M
Series A (2015): $50M with participation from Caisse de du00e9pu00f4t et placement du Quu00e9bec, CTI Life Sciences, Fonds de solidaritu00e9 FTQ, and Sanderling Ventures
Series B (2016): $100M led by Caisse de du00e9pu00f4t et placement du Quu00e9bec, CTI Life Sciences, Fonds de solidaritu00e9 FTQ, and Sanderling Ventures
Series D (2023): $80M supported by TB Alliance and Fonds de Developpement Économique
Key Investors in DalCor Pharmaceuticals
TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. They aim to ensure equitable access to faster, better TB cures through innovative science and global partnerships.
Caisse de dépt et placement du Québec
Caisse de dépt et placement du Québec is a full-service portfolio investment company managing institutional funds, primarily from public and private pension and insurance funds in Quebec since 1965.
CTI Life Sciences
CTI Life Sciences Fund is a Canadian venture capital firm specializing in catalyzing innovative ideas into scalable biotech companies, with a focus on therapeutic modalities and long-term value creation.
What's next for DalCor Pharmaceuticals?
With the recent major strategic investment, DalCor Pharmaceuticals is poised for significant growth and advancement. This capital infusion is expected to accelerate the ongoing Dal-GenE-2 Phase 3 clinical trial, potentially bringing dalcetrapib closer to market. The company's focus on precision medicine for cardiovascular diseases, a prevalent and high-need area, suggests a strategic expansion of its research and development efforts. Future endeavors may include further clinical studies, potential partnerships for commercialization, and the exploration of additional therapeutic targets within their precision medicine framework. The substantial backing underscores investor confidence in DalCor's innovative approach to tackling cardiovascular health.
See full DalCor Pharmaceuticals company page
